<DOC>
	<DOCNO>NCT00799968</DOCNO>
	<brief_summary>Comparative trial urokinase ( UK ) 12 hours（UK-12h）or 24 hour ( UK-24h ) produce similar result acute pulmonary thromboembolism ( PTE ) thrombolysis . It unclear whether infusion time reduce . The aim study investigate efficacy safety weight adjust dosage UK-2h ( 20 000 IU/Kg ) regime Uk-12h regime select patient PTE Chinese population .</brief_summary>
	<brief_title>12-h 2-h Urokinase Regimes Pulmonary Thromboembolism China</brief_title>
	<detailed_description>Pulmonary thromboembolism ( PTE ) , frequent life-threatening complication deep vein thrombosis ( DVT ) , often underestimated diagnose . Effective early treatment decrease mortality , reverse right heart dysfunction reduce risk chronic thromboembolic pulmonary hypertension ( CTEPH ) post-thrombotic syndrome ( PTS ) . Thrombolysis prove rapid effective therapy reduce obstruction pulmonary circulation normalize hemodynamic parameter . The ultimate goal thombolytic therapy disease minimize early morbidity mortality prevent recurrence without provoke excessive bleeding . Currently , choice thrombolytic agent regimens ( either UK rt-PA ) mostly base personal regional preference . A load dose UK 4400 IU/kg follow 2200 IU/kg/hour 12 hour ( UK-12h ) , rt-PA 100 mg infusion 2 hour recommend acute PTE treatment . However , increase evidence suggest UK infusion concentrate time reduce . 100 mg/2 h rt-PA novel dose regimen UK ( 3 million U/2 h ) compare . The result indicate 2-h regimen rt-PA 2h UK exhibit similar efficacy safety treatment acute PTE . UK-2h ( 20 000U/Kg ) regimen combine low molecular weight heparin ( LMWH ) use Chinese population.No severe bleed allergic reaction occur thrombolytic group . This dosage much low use Goldhaber et al , efficacy prominent . Until , study report compare UK-2h ( 20 000U/Kg ) regimen UK regimen ( UK-12h ) . A relative low dosage UK 2-h regimen body weight adjust may alternative choice treat PTE patient Chinese population.Considering low cost convenience regimen , efficacy safety UK-2h regimen ( 20 000U/Kg ) ACCP-approved UK-12h regimen treat acute PTE compared.The study conduct patient massive PTE shock hypotension and/or without shock hypotension right ventricular dysfunction . The clinical efficacy , emboli dissolve efficacy safety evaluate .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<criteria>PTE confirm either high probability ventilationperfusion lung scanning ( V/Q scan ) CTPA . massive PTE patient haemodynamic instability and/or cardiogenic shock Anatomic obstruction 2 lobes CTPA and/or defect 7 segment V/Q scan evidence right ventricular dysfunction ( RVD ) pulmonary hypertension echocardiography Symptoms within 15 day Written inform consent obtain patient randomization Received parenteral heparin 72 hour Known allergic urokinase Thrombolytic contraindication : 1. active bleed spontaneous intracranial hemorrhage ; 2. major surgery , organ biopsy recent puncture noncompressible vessel le 10 day ; 3. cerebral arterial thrombosis within 2 month ; 4. gastrointestinal bleeding within 10 day ; 5. major trauma within past 15 day ; 6. neurosurgery ophthalmologic operation 30 day ; 7. uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg ) ; 8. recent external cardiac resuscitation manoeuvre ; 9. platelet count &lt; 100 000/mm3 admission ; 10. pregnancy , puerperium lactation 2 week ; 11. infectious pericarditis endocarditis ; 12. severe hepatic kidney dysfunction ; 13. hemorrhagic retinopathy due diabetes ; 14. know bleeding disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Thrombolytic therapy</keyword>
	<keyword>Urokinase</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>